Sarepta Therapeutics, Inc.
NASDAQ:SRPTBiotechnology
+$0.29 today
- Market cap
- $1.56B
- Beta
- 0.20
- P/E (TTM)
- 27.8
- EPS (TTM)
- $0.62
Volume 1.86M
Average 3.08M
SRPT Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Sarepta Therapeutics, Inc.NASDAQ: SRPT
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue dips below year-ago levels
Q1 FY2026 cost of revenue of $119.36M fell 13.2% year over year, behind the +102.3% change in trailing-twelve-month cost of revenue. Sequentially, it fell 70.1% from the prior quarter. Over 3 fiscal years it compounded at +84.7% a year.
Context
- Cost of revenue amounted to 40.1% of revenue in FY2025, up 23.3 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -13.2% toward the trailing-twelve-month pace of +102.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 881.5M USD
- Year-over-year change
- +176.2%
- 4-year CAGR
- +73.6%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 881.5M | +176.2% |
| FY2024 | 2024-12-31 | 319.1M | +112.2% |
| FY2023 | 2023-12-31 | 150.34M | +7.4% |
| FY2022 | 2022-12-31 | 139.99M | +44.2% |
| FY2021 | 2021-12-31 | 97.05M | — |
Cost of Revenue vs competitors
How SRPT compares with its peers on the latest reported figures
- SRPT's LTM Mar 2026 cost of revenue of $821.4M is the 2nd highest of the 11 companies compared; the peer median is $10.75M.
- Its year-over-year change of +102.3% is the 5th highest of 10, against a peer median of +91.9%.
- Cost of revenue amounts to 37.6% of revenue for SRPT, versus a peer median of 17.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $974.34M | +141.9% | +58.9% | 20.3% | |
| LTM Mar 2026 | $821.4M | +102.3% | +84.7% | 37.6% | |
| LTM Jun 2026 | $180.19M | +250.5% | +17.1% | 17.9% | |
| LTM Mar 2026 | $167.7M | -26.7% | +28.1% | 253.7% | |
| LTM Mar 2026 | $42.41M | -26.6% | — | — | |
| LTM Sep 2026 | $17.04M | +44.2% | +4.3% | 1.8% | |
| LTM Mar 2026 | $4.46M | +106.0% | — | 6.2% | |
| LTM Mar 2026 | $1.72M | +351.6% | — | — | |
| LTM Mar 2026 | $781K | +91.9% | — | — | |
| LTM Jun 2026 | $521K | — | — | — | |
| LTM Mar 2026 | $0 | -100.0% | +10.1% | — | |
| Peer median (excluding SRPT) | $10.75M | +91.9% | +17.1% | 17.9% | |
Competitors are the stored peer set for SRPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 701.89M | 933.01M | 1.24B | 1.9B | 2.2B |
| Cost of Revenue | 97.05M | 139.99M | 150.34M | 319.1M | 881.5M |
| Gross Profit | 604.84M | 793.02M | 1.09B | 1.58B | 1.32B |
| Gross Margin | 86.2% | 85.0% | 87.9% | 83.2% | 59.9% |
| Research & Development | 771.18M | 877.09M | 877.39M | 804.52M | 1.52B |
| Selling, General & Admin | 282.66M | 451.42M | 481.87M | 557.87M | 478.94M |
| Operating Expenses | 1.06B | 1.33B | 1.36B | 1.36B | 1.97B |
| Depreciation & Amortization | 38.02M | 41.86M | 44.4M | 37.72M | 44.52M |
| EBITDA | (317.41M) | (594.85M) | (453.69M) | 316.89M | (647.97M) |
| EBITDA Margin | -45.2% | -63.8% | -36.5% | 16.7% | -29.5% |
| Operating Income | (459.71M) | (536.2M) | (267.82M) | 218.08M | (657.77M) |
| Operating Margin | -65.5% | -57.5% | -21.5% | 11.5% | -29.9% |
| Interest Income | 511K | 27.72M | 85.97M | 71.77M | 19.57M |
| Interest Expense | 63.53M | 53.25M | 22.01M | 18.39M | 9.73M |
| Other Income / Expenses | 40.76M | (153.76M) | (252.27M) | 42.69M | (44.45M) |
| Income Before Tax | (418.95M) | (689.96M) | (520.1M) | 260.77M | (702.23M) |
| Pre-Tax Margin | -59.7% | -73.9% | -41.8% | 13.7% | -31.9% |
| Income Tax Expense | (168K) | 13.53M | 15.88M | 25.54M | 11.19M |
| Net Income | (418.78M) | (703.49M) | (535.98M) | 235.24M | (713.41M) |
| Net Margin | -59.7% | -75.4% | -43.1% | 12.4% | -32.5% |
| EPS (Basic) | (5.15) | (8.03) | (5.80) | 2.47 | (7.13) |
| EPS (Diluted) | (5.15) | (8.03) | (5.80) | 2.34 | (7.13) |
| Weighted Avg Shares | 81.26M | 87.56M | 92.4M | 95.08M | 104.79M |
| Weighted Avg Shares (Diluted) | 81.26M | 87.56M | 92.4M | 107.88M | 104.79M |
Sarepta Therapeutics, Inc.
NASDAQ:SRPT
Intrinsic Alpha fair value
Locked
Current Price
$14.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.